Eli Lilly
What matters nowUpdated 6 h ago
- The latest development is the FDA approval of Jaypirca as a first-line treatment for untreated CLL or SLL on October 2, 2026, which extends the BTK inhibitor into frontline use 1; on October 9 Lilly reported exploratory TOGETHER-PsO data showing broader psoriasis and metabolic biomarker changes with Taltz plus Zepbound than with Taltz alone 2.
- The pooled 24/7 venue price of LLY is 1,176.81 USD, down 0.53% from the previous close of 1,183.07 USD, with a market cap of about 1.11 trillion USD and a P/E of 39.5. Recent pipeline news includes the EloraTZP Phase 2b combination of eloralintide and tirzepatide, which produced up to 23.3% weight loss at 48 weeks against 14.8% with tirzepatide 15 mg 3, and retatrutide TRIUMPH-2 detail showing 20.8% weight loss at 12 mg, published in The Lancet 4.
- Foundayo, the oral GLP-1 approved for obesity on April 1, 2026, met non-inferiority against insulin glargine on major adverse cardiovascular events in ACHIEVE-4, although the point estimates favored Foundayo and the confidence intervals include no difference 5; the FDA approved the once-weekly basal insulin Onswik for type 2 diabetes on September 24, 2026 6.
- Trailing twelve-month revenue is 79.67 billion USD, up 49.6% year on year, with EPS of 29.80 USD up 94.8%, a gross margin of 83.4% and a net margin of 33.5% (as of June 30, 2026); net debt is 45.96 billion USD. Insiders sold 31,828 shares worth 34.6 million USD over the last 180 days across five sales, four of them planned, and bought none.
- Next up is the Q3 2026 earnings call on October 29, 2026 at 14:00 UTC (not yet confirmed), and the US September CPI release on October 14 at 12:30 UTC. Retatrutide's BLA submission to the FDA is planned for Q1 2027 4. Polymarket prices an 81.5% chance of no change in Fed rates after the October 2026 meeting and 17.5% for a 25 bp increase.
Eli Lilly press release · Oct 2
Eli Lilly press release · Oct 9
Eli Lilly press release · Sep 30
Eli Lilly press release · Sep 29
Eli Lilly press release (PR Newswire) · Sep 30
Healio · Sep 24
Eli Lilly and Company is a US pharmaceutical company that discovers, develops and sells prescription medicines. Its growth is driven by incretin-based obesity and diabetes medicines Mounjaro and Zepbound, with oncology, neuroscience and immunology products and a deep pipeline of next-generation metabolic drugs.
How it makes money
Lilly sells branded prescription medicines to wholesalers, pharmacies, hospitals and direct-to-patient channels, mainly in the US and then in international markets. Revenue is driven by unit volume and realized price. Mounjaro and Zepbound alone were 56 percent of 2025 total revenue, so the company trades largely on incretin demand, pricing and new launches such as the oral obesity pill Foundayo. Research spending is high, with about $13.3 billion of R&D expense in 2025.
Last 12 monthsChart & venues →
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Biggest businessesAll products & projects →
Mounjaro
Largest revenue line; Q2 2026 revenue $9.94B.
Zepbound
Q2 2026 revenue $4.93B; FY2025 revenue up 175%.
Verzenio
FY2025 revenue $5.72B, up 8% vs FY2024.
Kisunla
Q2 2026 revenue $167M.
Latest newsAll news →
Taltz plus Zepbound shows broader biomarker changes than Taltz alone in psoriasis
On October 9, 2026 Lilly reported exploratory biomarker data from the TOGETHER-PsO Phase 3b trial, presented at Fall Clinical Dermatology.
Lilly presents 21 dermatology presentations at Fall Clinical 2026
Lilly announced on October 5, 2026 that it would present 21 dermatology presentations at the Fall Clinical Dermatology Conference in Las Vegas, held October 8-11.
FDA approves Jaypirca as first-line treatment for untreated CLL/SLL
The FDA approved Jaypirca (pirtobrutinib) on October 2, 2026 as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
EloraTZP Phase 2b: eloralintide plus tirzepatide beats tirzepatide 15 mg
Lilly reported Phase 2b results for EloraTZP, a combination of its amylin agonist eloralintide and tirzepatide, on September 30, 2026.
Foundayo ACHIEVE-4: MACE-4 non-inferiority met vs insulin glargine, not significant
Lilly reported detailed ACHIEVE-4 results for Foundayo on September 30, 2026, showing the oral GLP-1 met non-inferiority against insulin glargine on major adverse cardiovascular events.
Retatrutide TRIUMPH-2 detail: 20.8% weight loss at 12 mg, published in The Lancet
Lilly presented detailed TRIUMPH-2 results for retatrutide at the EASD meeting in Milan on September 29, 2026, with a simultaneous Lancet publication.
Products & businesses
Mounjaro
Largest revenue line; Q2 2026 revenue $9.94B.
Zepbound
Q2 2026 revenue $4.93B; FY2025 revenue up 175%.
Verzenio
FY2025 revenue $5.72B, up 8% vs FY2024.
Kisunla
Q2 2026 revenue $167M.
Jaypirca
Q2 2026 revenue $192M; EC approved monotherapy for CLL across all lines.
Foundayo (orforglipron)
FDA approved for obesity on 2026-04-01; Q2 2026 revenue $98M; type 2 diabetes submitted in the US.
What it's building next
Segments
| Segment | Revenue | Share | |
|---|---|---|---|
| Mounjaro Tirzepatide for type 2 diabetes and related use; the largest product by revenue in 2025. | $22.96B | 35.2% | |
| Zepbound Tirzepatide for chronic weight management; almost entirely US revenue in 2025. | $13.54B | 20.8% | |
| Verzenio Oncology drug for breast cancer. | $5.72B | 8.8% | |
| All other products Trulicity, Taltz, Jardiance, Olumiant, Emgality and other products combined; roughly flat in 2025. | $22.95B | 35.2% |
Fiscal 2025 · from the annual report
Valuation & fundamentals
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price.
Financial statements
| Metric | TTM | Q2 FY2026 2026-06-30 | Q1 FY2026 2026-03-31 | Q4 FY2025 2025-12-31 | Q3 FY2025 2025-09-30 | Q2 FY2025 2025-06-30 | Q1 FY2025 2025-03-31 | Q4 FY2024 2024-12-31 | Q3 FY2024 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.67B | $22.97B +48% | $19.80B +56% | $19.29Bd +43% | $17.60B +54% | $15.56B +38% | $12.73B +45% | $13.53Bd +45% | $11.44B +20% |
| Gross profit | $66.44B | $19.71Bd +50% | $16.22Bd +54% | $15.92Bd +43% | $14.59Bd +57% | $13.11Bd +44% | $10.50Bd +48% | $11.13Bd +47% | $9.27Bd +21% |
| Net income | $26.71B | $7.09B +25% | $7.40B +168% | $6.64Bd +51% | $5.58B +475% | $5.66B +91% | $2.76B +23% | $4.41Bd +101% | $970.3M |
| EPS (diluted) | $29.80 | $7.94 +26% | $8.26 +170% | $7.39d +51% | $6.21 +480% | $6.29 +92% | $3.06 +23% | $4.88d +102% | $1.07 |
| Operating cash flow | $28.08B | $10.69Bd +246% | $5.33B +220% | $3.22Bd +30% | $8.84Bd +138% | $3.09Bd +111% | $1.67B +43% | $2.47Bd | $3.71Bd +70% |
| Capital expenditure | — | — | — | — | — | — | — | — | — |
| Share buybacks | $6.17B | $1.60Bd +131% | $2.36B +96% | $1.51Bd -27% | $708.3Md +59% | $692.0Md | $1.20B | $2.05Bd | $446.1Md |
| Cash & equivalents | $8.95B | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B |
| Total debt | $54.91B | $54.91Bd | $43.37Bd | $42.50Bd | $42.51Bd | $39.90Bd | $38.52Bd | $33.81Bd | $31.12Bd |
| Shares outstanding | 941.4M | 941.4M | 941.7M | 943.4M | 945.4M | 946.5M | 947.7M | 948.2M | 949.3M |
| Metric | FY2025 2025-12-31 | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 |
|---|---|---|---|---|
| Revenue | $65.18B +45% | $45.04B +32% | $34.12B +20% | $28.54B |
| Cost of revenue | $11.05B +31% | $8.42B +19% | $7.08B +7% | $6.63B |
| Gross profit | $54.13Bd +48% | $36.63Bd +35% | $27.04Bd +23% | $21.91Bd |
| Research & development | — | — | — | $7.19B |
| Depreciation & amortization | $2.00B +13% | $1.77B +16% | $1.53B +0% | $1.52B |
| Interest expense | $895.0M +15% | $781.0M +61% | $485.9M +47% | $331.6M |
| Income tax | $5.09B +144% | $2.09B +59% | $1.31B +134% | $561.6M |
| Net income | $20.64B +95% | $10.59B +102% | $5.24B -16% | $6.24B |
| EPS (diluted) | $22.95 +96% | $11.71 +102% | $5.80 -16% | $6.90 |
| Dividends per share | $6.23 +15% | $5.40 +15% | $4.69 +15% | $4.07 |
| Diluted shares (weighted) | 899.3M | 904.1M | 903.3M | 904.6M |
| Operating cash flow | $16.81B +91% | $8.82B +108% | $4.24B -44% | $7.59B |
| Capital expenditure | — | — | — | — |
| Share buybacks | $4.11B +64% | $2.50B +233% | $750.0M -50% | $1.50B |
| Dividends paid | $5.38B +15% | $4.68B +15% | $4.07B +15% | $3.54B |
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B |
| Long-term debt (incl. current portion) | $40.87B | $29.47B | $19.10B | $14.82B |
| Total debt | $42.50Bd | $33.81Bd | $25.29Bd | $16.31Bd |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B |
| Total liabilities | $85.94Bd | $64.44Bd | $53.23Bd | $38.84Bd |
| Shareholders' equity | $26.54B | $14.27B | $10.77B | $10.65B |
| Shares outstanding | 943.4M | 948.2M | 950.2M | 950.3M |
From XBRL data in SEC filings. Small figures under each value: change vs the same period a year earlier. d = derived (e.g. Q4 = full year − first nine months).
NewsFull archive →
Taltz plus Zepbound shows broader biomarker changes than Taltz alone in psoriasis
On October 9, 2026 Lilly reported exploratory biomarker data from the TOGETHER-PsO Phase 3b trial, presented at Fall Clinical Dermatology.
Lilly presents 21 dermatology presentations at Fall Clinical 2026
Lilly announced on October 5, 2026 that it would present 21 dermatology presentations at the Fall Clinical Dermatology Conference in Las Vegas, held October 8-11.
FDA approves Jaypirca as first-line treatment for untreated CLL/SLL
The FDA approved Jaypirca (pirtobrutinib) on October 2, 2026 as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
EloraTZP Phase 2b: eloralintide plus tirzepatide beats tirzepatide 15 mg
Lilly reported Phase 2b results for EloraTZP, a combination of its amylin agonist eloralintide and tirzepatide, on September 30, 2026.
Foundayo ACHIEVE-4: MACE-4 non-inferiority met vs insulin glargine, not significant
Lilly reported detailed ACHIEVE-4 results for Foundayo on September 30, 2026, showing the oral GLP-1 met non-inferiority against insulin glargine on major adverse cardiovascular events.
Retatrutide TRIUMPH-2 detail: 20.8% weight loss at 12 mg, published in The Lancet
Lilly presented detailed TRIUMPH-2 results for retatrutide at the EASD meeting in Milan on September 29, 2026, with a simultaneous Lancet publication.
FDA approves Onswik, Lilly's once-weekly basal insulin for type 2 diabetes
The FDA approved insulin efsitora alfa-gobe, sold as Onswik, on September 24, 2026 as a once-weekly basal insulin for adults with type 2 diabetes.
Lilly completes acquisition of AtaiBeckley
Lilly announced on September 11, 2026 that it had completed its acquisition of AtaiBeckley, after the target's shareholders approved the transaction.
Lilly agrees to acquire Merida Biosciences for up to $2.875B in cash
Lilly signed a definitive agreement on August 31, 2026 to acquire Merida Biosciences, a Cambridge, Massachusetts biotech, for up to $2.875 billion in cash including milestones.
UK MHRA approves Foundayo (orforglipron) for weight management and type 2 diabetes
The UK Medicines and Healthcare products Regulatory Agency authorised Lilly's oral GLP-1 Foundayo for weight management and for type 2 diabetes on August 10, 2026.
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 positive; up to 22.6% weight loss
Lilly reported positive topline results from two Phase 3 trials of retatrutide, its triple GIP, GLP-1 and glucagon agonist.
Retatrutide meets primary endpoints in TRIUMPH-2 and TRIUMPH-3
Lilly reported that retatrutide met the primary endpoint in two more Phase 3 obesity trials: TRIUMPH-2 in adults with obesity and type 2 diabetes, and TRIUMPH-3 in adults with severe obesity and cardiovascular disease.
Lilly agrees to buy AtaiBeckley in all-cash deal worth up to $3.8B
Lilly agreed to acquire the clinical-stage psychedelic medicines company AtaiBeckley for up to $3.8 billion in cash.
Medicare GLP-1 Bridge starts July 1 with $50 monthly copay for Zepbound and Foundayo
Eligible Medicare Part D patients can get Zepbound and Foundayo for weight management for $50 a month under the Medicare GLP-1 Bridge program, which started July 1, 2026.
Michigan Supreme Court reverses appeals ruling in Lilly insulin pricing case
Lilly's quarterly report says the Michigan Supreme Court in July 2026 reversed a Michigan Court of Appeals decision in the insulin pricing litigation.
EU regulator backs Jaypirca for CLL across all treatment lines
The EU's medicines committee gave a positive opinion for Jaypirca (pirtobrutinib) in adults with chronic lymphocytic leukaemia across all lines of therapy, including patients who have not had a BTK inhibitor.
Lilly completes its acquisition of Centessa Pharmaceuticals
Lilly completed its acquisition of Centessa Pharmaceuticals on June 24, 2026, when the UK court order took effect under a scheme of arrangement.
Retatrutide hits 25% weight loss at 80 weeks in TRIUMPH-1 Phase 3
Lilly reported topline results from TRIUMPH-1, a Phase 3 obesity trial of retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist.
Lilly prices about $9 billion of senior notes due 2028 to 2066
Lilly completed a debt offering of about $9 billion of senior notes across eight series, maturing from 2028 to 2066, with net proceeds of about $8.94 billion.
Lilly's Q1 2026 revenue rose 56%; full-year guidance raised
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56%, mainly from volume growth partly offset by lower realized prices.
Lilly agrees to acquire Ajax Therapeutics for up to $2.3 billion
Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in total potential consideration, combining an upfront payment with milestones.
Lilly to acquire Kelonia Therapeutics for up to $7 billion
Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, including a $3.25 billion upfront payment, with the rest tied to clinical, regulatory and commercial milestones.
FDA approves Foundayo, Lilly's oral GLP-1 pill, for adults with obesity
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist taken without food or water restrictions, for adults with obesity and for adults with overweight who have at least one weight-related condition.
Lilly agrees to buy Centessa Pharmaceuticals for up to $7.8 billion
Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, of which about $6.3 billion is upfront.
Lilly agrees to buy Orna Therapeutics for up to $2.4 billion
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion in cash.
Lilly's Q4 2025 revenue rose 43%; 2026 guidance set at $80B-$83B
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, driven by volume growth for Mounjaro and Zepbound.
Eli Lilly reports fiscal Q3 2025 results: revenue $17.60B, up 54% from a year earlier
Eli Lilly filed a Form 8-K with the SEC on Oct 30, 2025, 7:03 AM ET, reporting an event dated Oct 30, 2025.
SEC filings
| Oct 8, 26 | 3 | Form 3: Initial insider ownership statement | sec.gov ↗ |
| Oct 7, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 22, 26 | 4 | Form 4: Sulzberger Gabrielle (Director) — award 4 sh | sec.gov ↗ |
| Sep 22, 26 | 4 | Form 4: LUCIANO JUAN R (Director) — award 14 sh | sec.gov ↗ |
| Sep 22, 26 | 4 | Form 4: Fyrwald J Erik (Director) — award 9 sh | sec.gov ↗ |
| Sep 22, 26 | 4 | Form 4: Alvarez Ralph (Director) — award 11 sh | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: Seymour Melissa (EVP, Global Quality) — gift 29 sh | sec.gov ↗ |
| Sep 4, 26 | 3/A | 3/A: Initial insider ownership statement (amended) | sec.gov ↗ |
| Sep 4, 26 | 4 | Form 4: Hernandez Edgardo (EVP & Pres., Mfg. Operations) — gift 13 sh | sec.gov ↗ |
| Sep 4, 26 | 4 | Form 4: Dozier Eric (EVP, Chief People Officer) — gift 216 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Sulzberger Gabrielle (Director) — award 4 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: LUCIANO JUAN R (Director) — award 13 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Fyrwald J Erik (Director) — award 8 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Alvarez Ralph (Director) — award 10 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Jonsson Patrik (EVP & President, LLY Int'l) — open-market sale 6,500 sh | sec.gov ↗ |
| Aug 17, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 11, 26 | 4 | Form 4: Zakrowski Donald A (SVP, Finance, & CAO) — open-market sale 2,000 sh | sec.gov ↗ |
| Aug 10, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 10, 26 | 4 | Form 4: Hakim Anat (EVP, GC & Secretary) — open-market sale 5,000 sh | sec.gov ↗ |
| Aug 7, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 5, 26 | 10-Q | 10-Q: Quarterly report for the period ended Jun 30, 2026 | sec.gov ↗ |
| Aug 5, 26 | 8-K | 8-K: Results of Operations (Item 2.02) | sec.gov ↗ |
| Aug 3, 26 | 4 | Form 4: Seymour Melissa (EVP, Global Quality) — option exercise 981 sh, tax withholding 439 sh | sec.gov ↗ |
| Jul 30, 26 | SCHEDULE 13D | SCHEDULE 13D: Activist/controlling ownership report (5%+) | sec.gov ↗ |
| Jul 24, 26 | SCHEDULE 13G/A | SCHEDULE 13G/A: Passive ownership report (5%+) (amended) | sec.gov ↗ |
Insider trades, 12 months
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Jonsson Patrik EVP & President, LLY Int'l | Sale 10b5-1 plan | 6.5K | $1175.10 | $7.6M |
| 2026-08-10 | Zakrowski Donald A SVP, Finance, & CAO | Sale 10b5-1 plan | 2.0K | $1185.01 | $2.4M |
| 2026-08-07 | Hakim Anat EVP, GC & Secretary | Sale 10b5-1 plan | 5.0K | $1190.00 | $6.0M |
| 2026-06-10 | Yuffa Ilya EVP&Pres, LLY USA&Global Capab | Sale 10b5-1 plan | 2.5K | $1150.77 | $2.9M |
| 2026-05-06 | LILLY ENDOWMENT INC Former 10% Shareholder | Sale | 15.8K | $995.36 | $15.8M |
| 2026-01-07 | LILLY ENDOWMENT INC 10% Owner | Sale | 292.1K | $1103.48 | $322.4M |
| 2026-01-05 | LILLY ENDOWMENT INC 10% Owner | Sale | 1.4K | $1085.01 | $1.5M |